Cozadd Bruce C's Form 4 filing
Jazz Pharmaceuticals plc (JAZZ) · filed Nov 20, 2025
- Accession no.
- 0001193210-25-000009
- Filed
- Nov 20, 2025
- Trade date
- Nov 18-20, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions. Open-market sales total $3.26M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Cozadd Bruce CCIK 0001193210 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | Ordinary Shares | SSaleDisposed | −3,384 | $180.09F1 | −$609,424.56 | 405,442 | Direct | |
| Nov 18, 2025 | Ordinary Shares | SSaleDisposed | −8,382 | $180.88F2 | −$1,516,136.16 | 397,060 | Direct | |
| Nov 18, 2025 | Ordinary Shares | SSaleDisposed | −5,517 | $181.81F3 | −$1,003,045.77 | 391,543 | Direct | |
| Nov 18, 2025 | Ordinary Shares | SSaleDisposed | −717 | $182.60F4 | −$130,924.2 | 390,826 | Direct | |
| Nov 20, 2025 | Ordinary Shares | AGrant or awardAcquired | +2,506 | $0.00 | $0 | 393,332 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $179.4013 to $180.38. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F2
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $180.4028 to $181.385. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F3
Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $181.41 to $182.30. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.
- F4
Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $181.59 to $182.77. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
Referenced by the price of 1 transaction in Table I.